Drugs / [11C]AZ14132516
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05818514 | Apr → Jul 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06053424 | Sep 2023 → Oct 2024 | Crohn disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]AZ14132516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06053424 ↗ |
| Modality | Diagnostic / imaging agent | “Injection of radioligand for PET examinations” NCT05818514 ↗ |
| Route | Intravenous | “The IV radioligand” NCT05818514 ↗ |
| Target | CCR9 | “measure the regional distribution and binding of \[11C\]AZ14132516 to CCR9 in the abdomen using PET-CT examination” NCT05818514 ↗ |